Cellular Therapy Using Epitope-Imprinted Composite Nanoparticles to Remove α-Synuclein from an In Vitro Model

Area of Science:

• Neuroscience
• Biotechnology
• Materials Science

Background:

• Neurodegenerative diseases like Parkinson's disease (PD) involve pathological protein aggregation.
• Alpha-synuclein (SNCA) is a key protein implicated in PD pathogenesis.
• Targeting toxic proteins with antibodies is a therapeutic strategy.

Purpose of the Study:

• To develop novel magnetic molecularly imprinted composite nanoparticles (MMIPs) targeting a specific SNCA peptide epitope.
• To characterize the synthesized MMIPs and assess their binding capabilities.
• To evaluate the therapeutic potential of MMIPs in an in vitro model.

Main Methods:

• Synthesis of MMIPs using a specific SNCA peptide as an epitope.
• Characterization of MMIPs using DLS, HPLC, ITC, BET, and SQUID analyses.
• Assessment of MMIPs' effect on brain endothelial cell viability and SNCA extraction from engineered cells.

Main Results:

• MMIPs were successfully synthesized and characterized.
• The MMIPs demonstrated effective extraction of SNCA from CRISPR/dCas9a-activated HEK293T cells.
• MMIP treatment showed no adverse effects on brain endothelial cell viability.

Conclusions:

• MMIPs targeting SNCA represent a promising therapeutic strategy for Parkinson's disease.
• The developed nanoparticles offer a novel approach for removing toxic protein aggregates.
• Further research is warranted to explore the in vivo efficacy of these MMIPs.